Hemo Organic Limited promoters Dineshbhai Shanabhai Patel and Sonalben Dineshbhai Patel disposed of a combined 10.15% of the company's total share capital through off-market sales on September 23, 2026.

The disclosures were filed under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Dineshbhai Patel sold 3,11,972 shares (9.00%), while Sonalben Patel sold 40,000 shares (1.15%). These transactions form part of a broader promoter divestment strategy announced earlier in September.

Shareholding movement

The table below captures the change in both promoters' shareholdings as a result of the disposals:

The total equity share capital of Hemo Organic remains unchanged at 34,65,900 equity shares of ₹10 each, aggregating to ₹3,46,59,000. The fully diluted share capital stands at 68,65,900 equity shares of ₹10 each, aggregating to ₹6,86,59,000, assuming full conversion of all outstanding convertible securities and warrants.

Context: broader promoter stake sale

This disposal forms part of a wider promoter divestment. Separately, Dineshbhai Patel and Sonalben Patel entered into share purchase agreements on September 22, 2026 to sell a combined 16.38% equity stake, comprising 5,67,958 fully paid-up equity shares, to the Jasani Family Trust and other buyers via an off-market route.

The buyers under those agreements include Mrs. Ketanaben Jasani, Mrs. Heema Makadia, M/s. V9BIZ Business Solution LLP, and Jasani Family Trust. None of the buyers are related to the promoter or promoter group, and the transactions do not fall within the definition of related party transactions. The share purchase agreements do not confer any special rights on the buyers, including no right to appoint directors, affirmative voting rights, veto rights, or pre-emptive rights.

Regulatory disclosures

The September 23, 2026 disposals were disclosed to BSE Limited under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The broader stake sale was disclosed to the exchanges under Regulation 30 and Regulation 30A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, referencing the SEBI Master Circular dated January 30, 2026. Hemo Organic is listed on BSE Limited.

Hemo Organic Limited has cancelled its board of directors meeting scheduled for September 23, 2026. The company cited unavoidable reasons for the cancellation in an intimation to BSE Limited dated September 21, 2026.

The cancelled meeting was originally convened to consider proposals for raising funds through various permissible modes, including qualified institutions placement (QIP) and preferential allotment. The board had planned to approve the issuance of equity shares or convertible securities.

Previous Agenda Details

The earlier agenda included considering the issuance of equity shares and convertible securities, including convertible warrants. The company was exploring options to raise funds in one or more tranches through:

• Preferential allotment
• Private placement
• Qualified institutions placement (QIP)
• Rights issue
• Further public issue

These actions required statutory approvals and consent from members. The board was also set to consider any ancillary actions required for such fund raising.

Regulatory Compliance

The initial disclosure regarding the meeting was made pursuant to Regulation 29(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Ayush Dharmendrabhai Jasani, Chairman and Additional Director, signed the intimation letter addressed to BSE Limited.

In compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window had been closed starting from business closing hours on September 19, 2026. This restriction continues until 48 hours after the conclusion of the board meeting, although the meeting itself is now cancelled.